|
| |
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
First published online August 6, 2004
Journal of Experimental Biology 207, 3233-3242 (2004)
Published by The Company of Biologists 2004
doi: 10.1242/jeb.01049
Review Article |
Erythropoietin and the hypoxic brain
Institute of Physiology and Pathophysiology, University of Heidelberg, Im Neuenheimer Feld 326, D-69120 Heidelberg, Germany
e-mail: hugo.marti{at}pio1.uni-heidelberg.de
Accepted 22 April 2004
Normal tissue function in mammals depends on adequate supply of oxygen through blood vessels. A discrepancy between oxygen supply and consumption (hypoxia) induces a variety of specific adaptation mechanisms at the cellular, local and systemic level. These mechanisms are in part governed by the activation of hypoxia-inducible transcription factors (HIF-1, HIF-2), which in turn modulate expression of hypoxically regulated genes such as those encoding vascular endothelial growth factor (VEGF) and erythropoietin (EPO).
EPO is a glycoprotein that is produced mainly by interstitial fibroblasts in the kidneys of the adult and in hepatocytes in the foetus. Released into the circulation, EPO makes its way to the bone marrow, where it regulates red cell production by preventing apoptosis of erythroid progenitor cells. Recently, EPO has emerged as a multifunctional growth factor that plays a significant role in the nervous system. Both EPO and its receptor are expressed throughout the brain in glial cells, neurones and endothelial cells. Hypoxia and ischaemia have been recognised as important driving forces of EPO expression in the brain. EPO has potent neuroprotective properties in vivo and in vitro and appears to act in a dual way by directly protecting neurones from ischaemic damage and by stimulating endothelial cells and thus supporting the angiogenic effect of VEGF in the nervous system. Thus, hypoxia-induced gene products such as VEGF and EPO might be part of a self-regulated physiological protection mechanism to prevent neuronal injury, especially under conditions of chronically reduced blood flow (chronic ischaemia).
In this review, I will briefly summarize the recent findings on the molecular mechanisms of hypoxia-regulated EPO expression in general and give an overview of its expression in the central nervous system, its action as a growth factor with non-haematopoietic functions and its potential clinical relevance in various brain pathologies.
Key words: hypoxia, ischaemia, neuroprotection, angiogenesis, VEGF, preconditioning, tolerance
Related articles in JEB:
This article has been cited by other articles:
|
|
 |
|
  M. Garcia-Ramirez, C. Hernandez, and R. Simo Expression of Erythropoietin and Its Receptor in the Human Retina: A comparative study of diabetic and nondiabetic subjects Diabetes Care, June 1, 2008; 31(6): 1189 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Casals-Pascual, R. Idro, N. Gicheru, S. Gwer, B. Kitsao, E. Gitau, R. Mwakesi, D. J. Roberts, and C. R. J. C. Newton High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria PNAS, February 19, 2008; 105(7): 2634 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Bavis, F. L. Powell, A. Bradford, C. C.W. Hsia, J. E. Peltonen, J. Soliz, B. Zeis, E. K. Fergusson, Z. Fu, M. Gassmann, et al. Respiratory plasticity in response to changes in oxygen supply and demand Integr. Comp. Biol., October 1, 2007; 47(4): 532 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tringali, G. Pozzoli, L. Lisi, and P. Navarra Erythropoietin Inhibits Basal and Stimulated Corticotropin-Releasing Hormone Release from the Rat Hypothalamus via a Nontranscriptional Mechanism Endocrinology, October 1, 2007; 148(10): 4711 - 4715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hernandez, A. Fonollosa, M. Garcia-Ramirez, M. Higuera, R. Catalan, A. Miralles, J. Garcia-Arumi, and R. Simo Erythropoietin Is Expressed in the Human Retina and It Is Highly Elevated in the Vitreous Fluid of Patients With Diabetic Macular Edema. Diabetes Care, September 1, 2006; 29(9): 2028 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Qutub and A. S. Popel A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1{alpha}. J. Cell Sci., August 15, 2006; 119(Pt 16): 3467 - 3480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wei, B. H. Han, Y. Li, C. L. Keogh, D. M. Holtzman, and S. P. Yu Cell Death Mechanism and Protective Effect of Erythropoietin after Focal Ischemia in the Whisker-Barrel Cortex of Neonatal Rats J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 109 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. O. Ogunshola, V. Djonov, R. Staudt, J. Vogel, and M. Gassmann Chronic excessive erythrocytosis induces endothelial activation and damage in mouse brain Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R678 - R684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Pearce Hypoxic regulation of the fetal cerebral circulation J Appl Physiol, February 1, 2006; 100(2): 731 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Milano and R. Collomp Erythropoietin and neuroprotection: a therapeutic perspective Journal of Oncology Pharmacy Practice, December 1, 2005; 11(4): 145 - 149. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Soliz, V. Joseph, C. Soulage, C. Becskei, J. Vogel, J. M. Pequignot, O. Ogunshola, and M. Gassmann Erythropoietin regulates hypoxic ventilation in mice by interacting with brainstem and carotid bodies J. Physiol., October 15, 2005; 568(2): 559 - 571. [Abstract] [Full Text] [PDF]
|
|
